TSX runs higher on rate cut expectations
Investing.com -- Exicure Inc (NASDAQ:XCUR) stock jumped 25% after the clinical-stage biotechnology company announced it has completed the last patient visit in its Phase 2 clinical trial of GPC-100 for multiple myeloma patients undergoing stem cell transplant.
The company expects to release topline results from the study in the fourth quarter of 2025. The trial is evaluating whether GPC-100, a small molecule CXCR4 antagonist, can improve the mobilization of hematopoietic stem cells from bone marrow into peripheral blood for collection and use in autologous stem cell transplant procedures.
According to data presented at ASH 2024, GPC-100 appears to differentiate itself from current treatments by the speed at which it mobilizes stem cells. The drug requires administration just 45 minutes before stem cell collection, potentially offering logistical advantages over traditional mobilization methods.
Dr. Muthalagu Ramanathan, Director of the Myeloma Program at U Mass Memorial Health, highlighted the potential benefit for patients, noting that traditional mobilization methods require patients to receive injections the night before procedures, adding logistical challenges.
Beyond multiple myeloma, Exicure is planning a Phase 1 study in acute myeloid leukemia patients and is exploring potential collaborations that would leverage GPC-100’s capabilities in cell and gene therapy applications.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.